A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Inclusion Criteria: * Written informed consent must be obtained from the subject. * Histologically documented primary skin angiosarcoma. * Locally advanced or locally recurrent angiosarcoma, and not eligible for curative surgery, chemoradiotherapy or radiotherapy. (Including cases where the individual refuses treatment.) * Measurable disease, as defined by RECIST v1.1. * The longest diameter of the entire target lesion is 15 cm or less. * ECOG performance status score of Grade 0 to 2 Exclusion Criteria: * Apparent disseminated tumor lesions. * Hereditary fructose intolerance. * Phenylketonuria. * Any serious concomitant disease that precludes completion of the study treatment. * The target lesion has received radiation exceeding 75 Gy.